Beta Bionics iLet Bionic Pancreas

The iLet Bionic Pancreas is a tubed insulin pump whose defining feature is its software, not its hardware: it is designed to be set up with only your body weight — no basal rates, no insulin-to-carb ratios, and no correction factors.¹¹ Because the dosing logic is so different from every other pump, the iLet is best understood and ranked as its own delivery device.

Form factor & wear. It is a durable, tubed pump (not a patch), weighing about 110 g with a full cartridge, with a colour touchscreen and an IPX8 water-resistance rating (immersion to ~12 feet for 30 minutes).¹² Insulin sits in an ~180-unit fillable cartridge, or you can use a 160-unit (1.6 mL) prefilled Fiasp cartridge.¹²¹¹ It connects to the body through a standard tubed infusion set, with Teflon (6 mm, 9 mm) sets worn 2 to 3 days and steel (6 mm, 8 mm) sets 1 to 2 days.¹¹

Reliability & occlusion detection. A dedicated occlusion alarm suspends insulin when flow is blocked and must be acknowledged before dosing resumes, alongside low-insulin and "insulin out" alarms.¹¹ In the pivotal trial, infusion-set failures occurred at roughly 1.3% per day — essentially the same rate as the well-established Tandem Control-IQ pump.¹¹ The control algorithm runs every 5 minutes and will fully suspend basal insulin for low or rapidly falling glucose.¹¹

Open FDA software corrections. Three Class II records remain open. Z-1996-2026 covers 1,080 systems on host 1.4.2/1.4.3 paired with Dexcom G7, where delayed readings can lead to dosing from non-CGM inputs; update to 1.4.4 or later.⁴ Z-2513-2026 covers 4,580 pumps on firmware through 3.3.6, where a lock-screen failure can block meal announcements and cartridge changes; update to 3.3.7 or later.⁵ Z-1809-2026 covers 15 systems on old software where Limited Access Mode can be bypassed, permitting an unauthorized meal or therapy action; update through the app.⁶ Scope and remedy depend on the installed version, so this is not a claim that every current iLet has every defect.

Which CGMs, algorithms & DIY it works with. The iLet pairs with Dexcom G6, Dexcom G7, Dexcom G7 15 Day, and Abbott FreeStyle Libre 3 Plus; the Dexcom sensors can be calibrated from the pump, the Libre cannot.¹¹¹³⁷ Crucially, it is a closed ecosystem: it is cleared to run only its own FDA-cleared dosing software — not DIY/open-source systems or any third-party algorithm.¹⁴¹¹ It is cleared for rapid-acting U-100 insulin only — Humalog (lispro), NovoLog (aspart), and Fiasp.¹¹

How dosing works. Three algorithms run in parallel — an adaptive basal algorithm, a model-predictive-control bolus algorithm, and a separate meal-dose algorithm — and they adapt continuously to your needs.¹¹ Instead of counting carbs, you announce a meal as "usual for me," "more," or "less," separately for breakfast, lunch, and dinner.¹¹ The only adjustable setting is a glucose target ("Usual" 120, "Lower" 110, or "Higher" 130 mg/dL).¹¹

Phone bolusing. The guides describe none. Meal announcements and dosing are entered on the pump's own touchscreen, while the companion smartphone app mirrors glucose, trend, and alerts.¹⁵

Evidence. Across multicentre randomised trials in adults and in youth 6–17, the iLet lowered HbA1c by about 0.5% and raised time-in-range by roughly 2.4–3.4 hours per day versus standard care, without increasing hypoglycaemia, with the largest gains in people starting at high HbA1c.¹⁶¹⁷¹⁸ It also improved control in cystic-fibrosis-related diabetes.¹⁹

Real-world data, published openly. In June 2026 Beta Bionics announced what it described as the first near-real-time public outcomes dashboard from an automated-insulin-delivery manufacturer. It covers 100% of iLet patients who meet two pre-stated criteria — a provider-reported baseline HbA1c, and at least two weeks of uploaded CGM data — with no additional company-reported exclusions.¹²⁰ Alongside it, three years of post-market data (19 May 2023 – 19 May 2026), discussed at ADA 2026, show time in range improving by 25% in that group.² Read that number carefully: it is a within-cohort change among users who upload their data and had a baseline on file — a self-selected group — not a head-to-head comparison against another system, and no baseline value is given, so whether "25%" is a relative or an absolute change is not stated. The genuinely notable part is the published inclusion rule and the lack of additional company-reported filtering; the site does not independently claim that no other manufacturer meets that standard.

Access & cost (US). The iLet is FDA-cleared and US-only.¹⁴ Express Scripts has added it to its commercial national formulary, which can sharply reduce the up-front pump cost for plans that cover it under the pharmacy benefit.²¹

Current companion features (US). Bionic Circle is already available for remote monitoring/sharing with up to 10 followers; it is not an upcoming feature. Beta Bionics also offers Color iLet to new patients, plus Pause Insulin on the pump.⁸ These are current US-product features, not evidence of access outside the system's US label.

The bigger hardware change is Mint, the company's first tubeless patch pump, designed to pair with the dosing algorithm the iLet already runs. Mint was FDA-cleared through the 510(k) pathway (decision 11 September, announced 14 September 2026). Beta Bionics expects to begin a full U.S. launch in the first quarter of 2027, sold only through pharmacies.¹⁰ That is a company launch target, not an approval date — treat it as such.

The longer-term roadmap returns to the project's origin: a bihormonal version that doses both insulin and glucagon.¹⁹

Next sensor pairing. Senseonics and Beta Bionics announced Eversense 365–iLet integration on 14 September 2026, with integration and commercial launch targeted for Q4. Testing, validation and regulatory requirements remain conditions; this announcement does not establish availability today.⁹

Next algorithm, separate regulatory step. On 14 September Beta Bionics announced submission of 3D Intelligence, with three settings (the original algorithm, an optimized version, and a conservative version) under its own 510(k) review; it is not a released iLet feature at this review.¹⁰